The Effectiveness of Beta-blockers after Myocardial Infarction in Patients with Type 2 Diabetes

Beta-blocker therapy reduces mortality and reinfarction after myocardial infarction (MI), but randomized triais have not included subjects with diabetes as a primary subgroup of interest. A retrospective cohort study was conducted using the Saskatchewan Health Databases to determine the effects of beta-blockers after MI in patients with type 2 diabetes, under real-world conditions. New users of antidiabetic agents with MI were identified by prescription records and ICD-9 codes. Drug exposures were determined from prescription records. Hospitalizations and deaths were documented over 9 years. Re-hospitalization after MI was studied as a measure of safety. Beta-blockers were associated with improved survival on univariate but not multivariate analysis, after controlling for clinical characteristics and medications. Recurrent MI and re-hospitalization were not increased in the betablocker group compared to controls. Beta-blocker therapy post-MI was not independently associated with a reduction in mortality in type 2 diabetes, after adjusting for interventions that reduce cardiovascular risk.

Name thesis:degree_name

Master of Science

Discipline thesis:degree_discipline

Epidemiology and Biostatistics

Grantor dc:publisher

The University of Western Ontario

Year dc:date.issued

2004

Author dc:creator

• McDonald, Charlotte G.

Advisor dc:contributor.advisor

• Mahon, Jeff

• Diabetes mellitus
• type ii
• Myocardial infarction/drug therapy
• Betablockers
• adrenergic
• Saskatchewan
• Databases
• Outcomes Research

Language dc:language.iso

en

Handle dc:identifier.uri

https://hdl.handle.net/20.500.14721/39879

OAI identifier oai:identifier

oai:uwo.scholaris.ca:20.500.14721/39879